Noscapine, a mild microtubule-stabilizing drug used as cough medicine in several parts of the world, is being considered for clinical trials for SPG4-HSP in Australia, with pre-clinical studies ongoing [35,36]. The gene discussed is SPAST; the disease is hereditary spastic paraplegia.